

# Why do we need a stratified medicine approach in the management of rheumatoid arthritis?

ABOUT THE LECTURE

Great progress has been made in understanding the pathogenesis of rheumatoid arthritis (RA) and biologic targeted therapies have revolutionized treatment, but moving therapeutic intervention from the “try and see” approach to a rational, individualised-based algorithm remains elusive. We will review current literature on synovial biomarkers and discuss integrating synovial pathobiology into clinical therapeutic algorithms to predict response to biologic therapies to personalize treatment in RA.

**Speaker:** **Prof. Costantino Pitzalis**

*Professor & Head, Centre for Experimental Medicine and Rheumatology,  
William Harvey Research Institute, Barts and The London School of Medicine,  
Queen Mary University of London  
Director, Research ECAM Clinical Academic Group and the Arthritis Research UK Experimental Arthritis  
Treatment Centre*

**Hosts:** **Prof. Salvatore Albani**

*Professor, Duke-NUS Graduate Medical School  
Director, SingHealth Translational Immunology and Inflammation Centre*

**Prof. Julian Thumboo**

*Professor, Duke-NUS Graduate Medical School  
Head and Senior Consultant, Department of Rheumatology and Immunology,  
Singapore General Hospital*

**Co-Sponsor:** *Janssen Pharmaceuticals Inc. of Johnson & Johnson*

**Date:** Thursday , 30 October 2014

**Time:** 4.00 PM— 5.00 PM  
(Light refreshments will be served at 3.30 PM)

**Venue:** Duke-NUS Graduate Medical School  
Amphitheatre, Level 2

**Contact Person:** Ms Kathleen Chan, Duke-NUS Research Affairs Department  
Tel: 6516 7255 or Email: [kathleen.chan@duke-nus.edu.sg](mailto:kathleen.chan@duke-nus.edu.sg)

ABOUT THE SPEAKER

Costantino Pitzalis, M.D., Ph.D. is Director of an Arthritis Research UK Experimental Arthritis Treatment Centre at Barts dedicated to the development of new anti-arthritic drugs and experimental medicine. His major research interests focus on the cellular and molecular mechanisms of inflammation and autoimmunity in chronic arthritis applied in particular to rheumatoid and psoriatic arthritis, with emphasis on translational research and biomarkers discovery.

